Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Director Julie Mchugh sold 1,500 shares of the business’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $16.16, for a total transaction of $24,240.00. Following the transaction, the director now owns 80,908 shares in the company, valued at $1,307,473.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Ironwood Pharmaceuticals, Inc. (NASDAQ IRWD) traded down 0.19% on Thursday, reaching $15.80. 353,972 shares of the company’s stock were exchanged. The company’s market cap is $2.36 billion. Ironwood Pharmaceuticals, Inc. has a 52-week low of $12.48 and a 52-week high of $19.94. The firm’s 50 day moving average price is $15.92 and its 200 day moving average price is $17.12.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by $0.05. The company had revenue of $65.10 million for the quarter, compared to analysts’ expectations of $70 million. Ironwood Pharmaceuticals had a negative net margin of 52.97% and a negative return on equity of 333.83%. The business’s revenue was up 19.7% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.16) EPS. On average, analysts expect that Ironwood Pharmaceuticals, Inc. will post ($1.10) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Ironwood Pharmaceuticals, Inc. (IRWD) Director Sells $24,240.00 in Stock” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/07/ironwood-pharmaceuticals-inc-irwd-director-sells-24240-00-in-stock.html.

Several research firms recently weighed in on IRWD. ValuEngine upgraded shares of Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Mizuho restated a “buy” rating and set a $20.00 price target (down from $23.00) on shares of Ironwood Pharmaceuticals in a report on Friday, August 25th. BidaskClub upgraded shares of Ironwood Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, August 25th. Cowen and Company set a $20.00 price target on shares of Ironwood Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, August 21st. Finally, Wells Fargo & Company set a $19.00 price target on shares of Ironwood Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, July 22nd. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company. Ironwood Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $18.13.

Several hedge funds and other institutional investors have recently made changes to their positions in IRWD. Strs Ohio boosted its holdings in shares of Ironwood Pharmaceuticals by 132.1% during the 1st quarter. Strs Ohio now owns 6,500 shares of the biotechnology company’s stock valued at $110,000 after acquiring an additional 3,700 shares during the last quarter. Teacher Retirement System of Texas purchased a new stake in shares of Ironwood Pharmaceuticals during the 2nd quarter valued at about $192,000. Jane Street Group LLC purchased a new stake in shares of Ironwood Pharmaceuticals during the 1st quarter valued at about $194,000. Karp Capital Management Corp purchased a new stake in shares of Ironwood Pharmaceuticals during the 1st quarter valued at about $201,000. Finally, Raymond James Financial Services Advisors Inc. boosted its holdings in shares of Ironwood Pharmaceuticals by 8.0% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 12,161 shares of the biotechnology company’s stock valued at $207,000 after acquiring an additional 898 shares during the last quarter. 97.95% of the stock is currently owned by hedge funds and other institutional investors.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Receive News & Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.